|Ms. Anna Protopapas||Pres, CEO & Director||881.5k||N/A||1964|
|Mr. Brian C. DeSchuytner||Sr. VP of Fin. & Product Strategy||580.01k||N/A||1978|
|Dr. Timothy B. Lowinger||Chief Science & Technology Officer||606.13k||1.25M||1964|
|Dr. Michael Kaufman||Chief Manufacturing Officer||590.23k||N/A||1958|
|Dr. Arvin Yang M.D., Ph.D.||Sr. VP & Chief Medical Officer||533.54k||N/A||1976|
|Mr. Mikhail Papisov Ph.D.||Co-Founder||N/A||N/A||N/A|
|Mr. Ashish Mandelia||VP, Controller & Principal Accounting Officer||N/A||N/A||1974|
|Ms. Sarah Carmody||Exec. Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Ms. Alejandra Veronica Carvajal||Sr. VP & Chief Legal Officer||N/A||N/A||1974|
|Ms. Carla Poulson||Chief HR Officer||N/A||N/A||N/A|
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development of antibody drug conjugates (ADC) for cancer patients with unmet need. The company develops XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma; and XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumors, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. It also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. The company has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Mersana Therapeutics, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 9. The pillar scores are Audit: 7; Board: 9; Shareholder Rights: 8; Compensation: 9.